SpliceBio has dosed the first patient in the Part B dose-expansion portion of its phase 1/2 ASTRA clinical trial ( NCT06942572) evaluating SB-007 for the treatment of Stargardt disease.

First dose-expansion patient successfully received SB-007 SB-007 addresses the root cause of Stargardt disease with the potential to treat patients across all ABCA4 mutations SB-007 granted FDA ...